Pharmacovigilance Agreement. Either Party may terminate a particular Study under this Agreement immediately upon written notice to the other Party if (a) the Parties do not execute a Pharmacovigilance Agreement for such Study within the timeframe set forth in Section 4.5 or (b) the terminating Party determines in good faith that such Study represents an unjustified risk to the safety of patients in the applicable Study Field.
Appears in 2 contracts
Samples: Supply and Non Exclusive License Agreement (MAIA Biotechnology, Inc.), Supply and Non Exclusive License Agreement (MAIA Biotechnology, Inc.)
Pharmacovigilance Agreement. Either Party may terminate a particular Study under this Agreement immediately upon written notice to the other Party if (a) the Parties do not execute a Pharmacovigilance Agreement for such Study within the timeframe set forth in Section 4.5 or (b) the terminating Party determines in good faith that such Study represents an unjustified risk to the safety of patients in the applicable Study Field.Section
Appears in 1 contract
Samples: Supply and Non Exclusive License Agreement (MAIA Biotechnology, Inc.)
Pharmacovigilance Agreement. Either Party may terminate a particular Study under this Agreement immediately upon written notice to the other Party if (a) the Parties do not execute a Pharmacovigilance Agreement for such Study within the timeframe set forth in Section 4.5 or (b) the terminating Party determines in good faith that such Study represents an unjustified risk to the safety of patients in the applicable Study Fieldmay unreasonably affect patient safety.
Appears in 1 contract
Samples: Supply and Non Exclusive License Agreement (Angion Biomedica Corp.)
Pharmacovigilance Agreement. Either Party may terminate a particular Study under this Agreement immediately upon written notice to the other Party if (a) the Parties do not execute a Pharmacovigilance Agreement for such Study within the timeframe set forth in Section 4.5 or (b) the terminating Party determines in good faith that such Study represents an unjustified risk to the safety of patients in the applicable Study Fieldmay unreasonably adversely affect patient safety.
Appears in 1 contract
Samples: Supply and Non Exclusive License Agreement (Checkmate Pharmaceuticals, Inc.)